Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “escitalopram” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 12
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 12 pipeline programs matching "escitalopram" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

12 results for “escitalopram” Back to intelligence hub

Search results

  1. Escitalopram

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial
  2. Escitalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial
  3. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial
  4. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial
  5. escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Addiction

    phase 2 small molecule terminated

    1 trial
  6. Escitalopram

    Universal Integrated

    Major Depressive Disorder

    phase 1 small molecule completed

    1 trial
  7. Modafinil and Escitalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial
  8. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Major Depressive Disorder (MDD)

    small molecule active

    1 trial
  9. Escitalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder, Major

    small molecule completed

    1 trial
  10. Escitalopram (Oral antidepressant)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Depression - Major Depressive Disorder

    small molecule active

    1 trial
  11. Escitalopram Oxalate Tablets

    The First People's Hospital of Lianyungang

    Major Depressive Disorder

    small molecule active

    1 trial
  12. Placebo and Escitalopram

    Takeda

    Panic Disorder

    small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.